| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT03955146 | Kyntra Bio | Phase 3 | Terminated | 2023-03-20Actual |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsNCT03981822 | VRCA | Phase 2 | Completed | 2020-05-21Actual |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)NCT03987295 | ALEC | Phase 2 | Completed | 2024-06-05Actual |
| PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379 | CytomX Therapeutics | Phase 2 | Terminated | 2020-05-21Actual |
| Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03995108 | X4 Pharmaceuticals | Phase 3 | Completed | 2025-12-23Actual |
| Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT04003974 | Fulcrum Therapeutics | Phase 2 | Completed | 2021-01-28Actual |
| Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionNCT04004000 | Fulcrum Therapeutics | Phase 2 | Terminated | 2024-10-31Actual |
| Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaNCT04006119 | Alaunos Therapeutics | Phase 2 | Terminated | 2021-08-05Actual |
| A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyNCT04014335 | IONS | Phase 2 | Completed | 2024-02-08Actual |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805 | TGTX | Phase 2 | Terminated | 2022-05-22Actual |
| Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisNCT04023396 | ABVX | Phase 2 | Completed | 2023-02-23Actual |
| Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisNCT04028492 | Vanda Pharmaceuticals | Phase 3 | Completed | 2025-02-21Actual |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)NCT04029116 | SCYX | Phase 3 | Completed | 2021-09-01Actual |
| A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughNCT04030026 | Trevi Therapeutics | Phase 2 | Completed | 2022-05-27Actual |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsNCT04035733 | AKARI Therapeutics | Phase 2 | Completed | 2020-03-12Actual |
| A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)NCT04042844 | BioRestorative Therapies | Phase 2 | Recruiting | 2026-12Estimated |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.NCT04049266 | KOD | Phase 2, Phase 3 | Terminated | 2021-11-17Actual |
| Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisNCT04049448 | ABVX | Phase 2 | Completed | 2023-01-23Actual |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436 | Replimune, Inc. | Phase 2 | Active not recruiting | 2025-09Estimated |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)NCT04057040 | PTGX | Phase 2 | Completed | 2023-02-14Actual |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898 | MediciNova | Phase 2, Phase 3 | Active not recruiting | 2027-04Estimated |
| Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)NCT04059406 | IONS | Phase 2 | Terminated | 2023-03-28Actual |
| A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular InsertNCT04061044 | OCUL | Phase 3 | Completed | 2020-02-10Actual |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyNCT04067011 | Emergent BioSolutions | Phase 2 | Completed | 2020-03-05Actual |
| Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)NCT04068051 | AXSM | Phase 3 | Completed | 2020-09-22Actual |
| Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype ANCT04069533 | RCKT | Phase 2 | Unknown | 2025-02Estimated |
| Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/NCT04072315 | PLRX | Phase 2 | Completed | 2022-06-27Actual |
| NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesNCT04081103 | Glaukos Corporation | Phase 2 | Terminated | 2022-02-07Actual |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364 | MacroGenics | Phase 2, Phase 3 | Completed | 2024-01-15Actual |
| Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisNCT04091646 | ARQT | Phase 2 | Completed | 2020-08-18Actual |
Trial details
- Registry ID
- NCT03955146
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03981822
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03987295
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03993379
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03995108
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04003974
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04004000
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04006119
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04014335
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04016805
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04023396
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04028492
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04029116
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04030026
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04035733
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04042844
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04049266
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04049448
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04050436
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04057040
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04057898
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04059406
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04061044
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04067011
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04068051
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04069533
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04072315
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04081103
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04082364
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04091646
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.